Your browser doesn't support javascript.
A serum proteome signature to predict mortality in severe COVID-19 patients.
Völlmy, Franziska; van den Toorn, Henk; Zenezini Chiozzi, Riccardo; Zucchetti, Ottavio; Papi, Alberto; Volta, Carlo Alberto; Marracino, Luisa; Vieceli Dalla Sega, Francesco; Fortini, Francesca; Demichev, Vadim; Tober-Lau, Pinkus; Campo, Gianluca; Contoli, Marco; Ralser, Markus; Kurth, Florian; Spadaro, Savino; Rizzo, Paola; Heck, Albert Jr.
  • Völlmy F; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands.
  • van den Toorn H; Netherlands Proteomics Center, Utrecht, The Netherlands.
  • Zenezini Chiozzi R; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands.
  • Zucchetti O; Netherlands Proteomics Center, Utrecht, The Netherlands.
  • Papi A; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands.
  • Volta CA; Netherlands Proteomics Center, Utrecht, The Netherlands.
  • Marracino L; Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara, Ferrara, Italy.
  • Vieceli Dalla Sega F; Respiratory Section, Department of Translational Medicine, University of Ferrara, Ferrara, Italy and Respiratory Disease Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
  • Fortini F; Department of Translational Medicine University of Ferrara, Ferrara, Italy and Intensive Care Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy.
  • Demichev V; Department of Translational Medicine and Laboratory for Technology of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
  • Tober-Lau P; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
  • Campo G; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
  • Contoli M; Charité-Universitätsmedizin Berlin, Department of Biochemistry, Berlin, Germany.
  • Ralser M; The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London, UK.
  • Kurth F; The University of Cambridge, Department of Biochemistry and Cambridge Centre for Proteomics, Cambridge, UK.
  • Spadaro S; Charité-Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany.
  • Rizzo P; Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara, Ferrara, Italy.
  • Heck AJ; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Life Sci Alliance ; 4(9)2021 09.
Article in English | MEDLINE | ID: covidwho-1298278
ABSTRACT
Here, we recorded serum proteome profiles of 33 severe COVID-19 patients admitted to respiratory and intensive care units because of respiratory failure. We received, for most patients, blood samples just after admission and at two more later time points. With the aim to predict treatment outcome, we focused on serum proteins different in abundance between the group of survivors and non-survivors. We observed that a small panel of about a dozen proteins were significantly different in abundance between these two groups. The four structurally and functionally related type-3 cystatins AHSG, FETUB, histidine-rich glycoprotein, and KNG1 were all more abundant in the survivors. The family of inter-α-trypsin inhibitors, ITIH1, ITIH2, ITIH3, and ITIH4, were all found to be differentially abundant in between survivors and non-survivors, whereby ITIH1 and ITIH2 were more abundant in the survivor group and ITIH3 and ITIH4 more abundant in the non-survivors. ITIH1/ITIH2 and ITIH3/ITIH4 also showed opposite trends in protein abundance during disease progression. We defined an optimal panel of nine proteins for mortality risk assessment. The prediction power of this mortality risk panel was evaluated against two recent COVID-19 serum proteomics studies on independent cohorts measured in other laboratories in different countries and observed to perform very well in predicting mortality also in these cohorts. This panel may not be unique for COVID-19 as some of the proteins in the panel have previously been annotated as mortality markers in aging and in other diseases caused by different pathogens, including bacteria.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severity of Illness Index / Proteome / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Language: English Year: 2021 Document Type: Article Affiliation country: Lsa.202101099

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Severity of Illness Index / Proteome / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Language: English Year: 2021 Document Type: Article Affiliation country: Lsa.202101099